The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

The Journal of Immunology, 2008, 181, 6955 -6963
Copyright © 2008 by The American Association of Immunologists, Inc.
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Larmonier, N.
Right arrow Articles by Katsanis, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Larmonier, N.
Right arrow Articles by Katsanis, E.

Imatinib Mesylate Inhibits CD4+CD25+ Regulatory T Cell Activity and Enhances Active Immunotherapy against BCR-ABL– Tumors1

Nicolas Larmonier2,*,{dagger},{ddagger}, Nona Janikashvili*, Collin James LaCasse*,{dagger}, Claire Billerey Larmonier*,{dagger}, Jessica Cantrell*, Elaine Situ*, Tamara Lundeen*,{dagger}, Bernard Bonnotte§ and Emmanuel Katsanis*,{dagger},{ddagger}

* Department of Pediatrics, Steele Children’s Research Center, {dagger} Department of Immunobiology, and {ddagger} BIO5 Institute and Arizona Cancer Center, University of Arizona, Tucson, AZ 85724; and § Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche, IFR, Faculty of Medicine, Dijon, France


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Imatinib mesylate (Gleevec, STI571), a selective inhibitor of a restricted number of tyrosine kinases, has been effectively used for the treatment of Philadelphia chromosome-positive leukemias and gastrointestinal stromal tumors. Imatinib may also directly influence immune cells. Suppressive as well as stimulating effects of this drug on CD4+ and CD8+ T lymphocytes or dendritic cells have been reported. In the current study, we have investigated the influence of imatinib mesylate on CD4+CD25+FoxP3+ regulatory T cells (Treg), a critical population of lymphocytes that contributes to peripheral tolerance. Used at concentrations achieved clinically, imatinib impaired Treg immunosuppressive function and FoxP3 expression but not production of IL-10 and TGF-β in vitro. Imatinib significantly reduced the activation of the transcription factors STAT3 and STAT5 in Treg. Analysis of Treg TCR-induced signaling cascade indicated that imatinib inhibited phosphorylation of ZAP70 and LAT. Substantiating these observations, imatinib treatment of mice decreased Treg frequency and impaired their immunosuppressive function in vivo. Furthermore, imatinib mesylate significantly enhanced antitumor immune responses to dendritic cell-based immunization against an imatinib-resistant BCR-ABL negative lymphoma. The clinical applications of imatinib mesylate might thus be expanded with its use as a potent immunomodulatory agent targeting Treg in cancer immunotherapy.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Imatinib mesylate (Gleevec) therapy remains the standard of care for patients with chronic myelogenous leukemia (CML).3 Designed as a selective competitive inhibitor of the Abelson (ABL) tyrosine kinases (BCR-ABL, v-ABL, c-ABL), this drug leads to growth arrest or apoptosis (1, 2). Imatinib also displays strong activity against the platelet-derived growth factor receptor, c-kit receptor, ABL-related gene, and their fusion proteins (1, 2, 3) and thus has also been used for the therapy of gastrointestinal stromal tumors with mutations in c-kit (2).

However, the specificity of this molecule may be broader than originally expected, and it is becoming increasingly evident that imatinib also inhibits key tyrosine kinases in immune cells. The exact nature of imatinib effects (activation or suppression) on lymphocytes or dendritic cells remains controversial. Inhibition of CD4+ or CD8+ T cell proliferation and activation by imatinib has been documented (4, 5, 6, 7, 8). Some reports have further highlighted the negative effect of imatinib on the TCR-induced ZAP70 signaling pathway identifying the leukocyte-specific protein tyrosine kinase (Lck) as a potential molecular target (4, 9). Similarly, a negative modulation of dendritic cell (DC) development by imatinib and a down-regulation of their Ag-presenting function have also been described (10, 11, 12). In contrast to these findings, it has been reported that imatinib does not impede the immunogenicity of DC (13) and may enhance their Ag-presenting function (14). Additionally, some reports indicate that imatinib may foster DC-NK reciprocal activation, thereby promoting the antitumoral function of NK cells (15).

CD4+CD25+ regulatory T lymphocytes (Treg) critically contribute to the maintenance of self-tolerance and to the prevention of autoimmunity in animals and humans (16, 17). These suppressive cells have also been highlighted as major contributors in the establishment and persistence of cancer-induced immune tolerance (18, 19). Treg expansion detected in the blood, lymph nodes, and spleens of tumor-bearing hosts (20, 21, 22, 23) may result from the conversion of CD4+CD25– T cells into CD4+CD25+ Treg (24) or from the proliferation of naturally occurring Treg (25). Tumor-induced Treg compromise the function of anti-tumor effector CD8+ T cells, curtail CD4+ T cell help, impede Ag-presenting cell activity (18, 23, 26) and therefore represent a major obstacle for successful cancer immunotherapy. In support of this concept, studies in humans and in animal models have demonstrated that attempts to disrupt Treg suppressive activity promote antitumoral immunity (20, 27, 28). Different strategies have thus been evaluated to deplete or inactivate Treg and include the use of anti-CD25 Abs, the IL-2/diphtheria toxin fusion protein, the immunotoxin LMB-2, OX-40 Abs, or drugs such as cyclophosphamide (20, 26, 27, 29, 30, 31). However, no consensus has been reached regarding the optimal protocol to be used with immunotherapy.

Considering the broad nature of the tyrosine kinases targeted by imatinib mesylate and the prominent role of such proteins in Treg function, we reasoned that imatinib may be endowed with the potential to modulate Treg activity. We have therefore investigated the influence of imatinib on Treg in vitro and in vivo. Our results demonstrate that, in vitro, this tyrosine kinase inhibitor curtailed the immunosupressive activity of Treg and restrained forkhead box P3 (FoxP3) expression. Imatinib mesylate interfered with Treg TCR-signaling pathway as it reduced the phosphorylation of ZAP70 and LAT. The activation of the downstream transcription factors STAT3 and STAT5 was impeded by the drug. The physiologic consequences of imatinib treatment on antitumoral immune responses in vivo was also examined. Imatinib reduced the number and impaired the immunosuppressive function of Treg in vivo and acted synergistically with DC-based immunization against imatinib-resistant lymphoma. Taken together these findings support the use of this agent as an immunomodulator in cancer immunotherapy.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Disclosures
 References
 
Mice

Mice were housed under specific pathogen-free conditions and cared for according to the guidelines of the University of Arizona Institutional Animal Care and Use Committee. Six- to 8-wk-old female BALB/c (H2d), C57BL6 (H2b) and SCID/NCr mice were obtained from the National Cancer Institute and used for the experiments.

Cell lines

The murine leukemia and lymphoma cell lines 12B1 and A20 were cultured at 37°C and in 5% CO2 in RPMI 1640 medium (HyClone) supplemented with 10% heat-inactivated FBS (HyClone). The 12B1 cell line was obtained from Dr. Wei Chen (Cleveland Clinic, Cleveland, OH). Cells were tested routinely and found to be free of Mycoplasma contamination.

Imatinib mesylate

Commercially available 100 mg imatinib capsule content (Gleevec/Glivec, Norvartis) was dissolved in sterile distilled water (Sigma-Aldrich) at desired concentrations, aliquoted, and stored at –20°C for further in vitro and in vivo experiments. The biologic activity of the drug was tested every week on imatinib-sensitive 12B1 leukemia (BCR/ABL+) or imatinib-resistant A20 lymphoma (BCR/ABL–) using thiazolyl blue tetrazolium bromide (MTT) assays (Sigma-Aldrich).

Magnetic cell sorting and cultures

Spleens and lymph nodes isolated from BALB/c mice (naive tumor-free or A20 tumor-bearing) were dissociated. CD4+CD25+ and CD4+CD25– T lymphocytes were purified by magnetic cell sorting using mouse CD4+CD25+ T regulatory cell isolation kits and an autoMACS separator according to the manufacturers’ instructions (Miltenyi Biotec). Both CD4+ T lymphocyte populations (1 x 105 cells per well) were separately activated for 24 h in round-bottom 96-well plates coated with anti-CD3{epsilon} Ab (5 µg/ml, clone 145-2C11, BD Pharmingen) and 5 µg/ml soluble anti-CD28 Ab (clone 37.51, BD Pharmingen) in the presence of IL-2 (100 U/ml, R&D Systems).

Flow cytometry analysis and Abs

Cells (~106) were washed in PBS containing 3% heat-inactivated FBS and 0.09% sodium azide (Sigma-Aldrich) and were first incubated with an Fc receptor-blocking Ab (BD Pharmingen) for 5 min, then with saturating amounts of the appropriate combination of fluorochrome-conjugated Ab for 40 min. Cells were then washed and analyzed using a FACS calibur (Becton Dickinson Immunocytometry Systems). A minimum of 10,000 events was collected for each sample, and data analysis was performed with the CellQuest software (Becton Dickinson Immunocytometry Systems). For FoxP3 detection, CD4+CD25+ or CD4+CD25– T cells purified by magnetic cell sorting were fixed, permeabilized, stained using an allophycocyanin anti-mouse FoxP3 staining set following the provider’s instructions (Clone FJK-16, eBioscience), and analyzed by flow cytometry. For the monitoring of CD4+CD25+ Treg, cells were first stained with FITC-conjugated anti-CD4 (rat IgG2b; BD Pharmingen) and PE-conjugated anti-CD25 (rat IgG1; BD Pharmingen) Abs. Then cells were stained using eBioscience FoxP3 staining set as described above. Isotype control Abs were purchased from BD Pharmingen (PE-conjugated rat IgG1, FITC-conjugated rat IgG2a), or eBioscience (allophycocyanin-conjugated rat IgG1).

T cell proliferation and suppression assays

CD4+CD25– T cells (1 x 105) from naive BALB/c mice (H2d) were cocultured for 60 h in round-bottom 96-well plates with 1 x 105 mitomycin C-treated APC (CD90-depleted splenocytes from C57BL/6 mice, H2b) with or without activated CD4+CD25+ T cells (1 x 105) from BALB/c mice. [3H]Thymidine (ICN Pharmaceuticals) was then added (1 µCi per well) for an additional 12 h. The cells were then harvested using a 96-well cell harvester and the radioactivity measured on a Packard beta counter (Packard Biosciences). Cultures were set up in triplicate.

Detection of cytokine production by ELISA

The concentrations of IFN-{gamma}, IL-10, or TGF-β1 in cell culture supernatants (1 x 105 cells in 200 µl/well for 48 h) were determined using ELISA kits according to the manufacturer’s procedures (eBiosciences).

Detection of STAT3 and STAT5 phosphorylation by Western blotting

CD4+CD25– or CD4+CD25+ T cells purified as described above were preincubated for 2 h with or without imatinib and were then activated for 6 h with soluble anti-CD3{epsilon} (5 µg/ml), anti-CD28 Ab (5 µg/ml), and IL-2 (100U/ml). These conditions have been set up to allow the detection of STAT3 and STAT5 phosphorylation, an event that occurs within few hours following cell stimulation. Cells were lysed in lysis buffer (1% Nonidet P40, 50 mM Tris-HCl (pH 7.4), 2 mM EDTA, 100 mM NaCl, 0.2 mg/ml aprotinin, 0.2 mg/ml leupeptin, 1 mM PMSF, 10 mM NaF, 30 mM NaPPi, 10 mM Na3VO4) and Western blot analysis was then performed as described (23), using anti-phospho STAT3 (pTyr705), anti-STAT3, anti-phospho STAT5 (pTyr694), or anti-STAT5 Abs (Cell Signaling Technology). In other experiments, STAT3 activation was detected in Treg by DNA-binding transcription factor ELISA. Treg nuclear extracts were performed using a Nuclear Extract kit (Active Motif). Then STAT3 DNA-binding activity was measured with 10-µg nuclear extract using a STAT3 Trans-AM kit according to the manufacturer’s recommendations (Active Motif).

Analysis of ZAP-70 and LAT phosphorylation

ZAP-70 and LAT phosphorylation are early events in the transduction of TCR and CD28 signals in T cells. Therefore, purified CD4+CD25– or CD4+CD25+ T cells were pre-incubated for 2 h with or without imatinib and were immediately activated for 5 min with soluble anti-CD3{epsilon} (5 µg/ml) and anti-CD28 Ab (5 µg/ml). Cells were then lysed and analyzed by western blot as described above. Abs used were as follows: anti-phospho ZAP70 (pTyr 705), anti-ZAP70, anti-phospho LAT (pTyr694) or anti-LAT Abs (Cell Signaling Technology).

Bone marrow-derived DC

DC were generated from BALB/c bone marrow cells. Cells were harvested from femurs and tibias and filtered through a Falcon 100-µm nylon cell strainer (BD Biosciences). RBC were lysed in a hypotonic buffer (150 mM NH4Cl, 1 mM KHCO3, 0.1 mM Na2EDTA) and the marrow was cultured at a density of 5 x 105 cells/ml in complete RPMI medium (Life Technologies) containing 10% FBS (HyClone). Murine GM-CSF (PeproTech) and IL-4 (PeproTech) were added at a concentration of 10 ng/ml each. Complete RPMI medium containing GM-CSF and IL-4 was added on day 3. On day 5, medium was replaced and total A20 tumor cell lysate was added. On day 6, cells were activated for 24 h with LPS (0.1 µg/ml), and on day 7, cells were recovered, washed in PBS, and used as pulsed DC vaccines in chemoimmunotherapy experiments. A20 tumor cell lysate was prepared by six cycles of freezing in liquid nitrogen and thawing in a 37°C water bath, leading to 100% dead cells as assessed by trypan blue. DC cultures were pulsed with one equivalent tumor cell/DC.

Immunohistochemical staining

SCID mice were injected s.c. with 106 A20 cells or 5 x 103 12B1 cells and were treated with imatinib (gavage, 300 mg/kg daily for 7 days) when tumor became palpable (tumor diameter ~2–3 mm). Animals were euthanized 2 days after the end of the treatment. Tumors were removed, embedded in Tissue-Tek (Sakura Finetek), and snap-frozen in liquid nitrogen. Caspase 3 cleavage, a marker of apoptosis, was detected on methanol-fixed 5-µm cryostat sections after inhibition of endogenous peroxidase activity in 3% H2O2 and incubation with goat serum (KPL) and 1% BSA. Rabbit anti-mouse Ab recognizing the cleaved (active) form of caspase 3 (Cell Signaling Technology) and IgG isotype-matched control (Santa Cruz Biotechnology) were used. Sections were then incubated with biotinylated goat anti-rabbit Ab (KPL), then with streptavidin-peroxidase (KPL), and were stained with 3,3'-diaminobenzidine (Vector Laboratories). Slide examination of all tumor samples was performed independently by two investigators in a double blind manner.

Chemoimmunotherapy of A20 lymphoma with imatinib mesylate and DC vaccines

Female BALB/c mice (eight mice per group) inoculated at day 0 with A20 cells (5 x 105 cells in 0.1 ml PBS, tail vein injection) were treated at day 3 with imatinib mesylate (gavage, 300 mg/kg, twice daily for 7 days) or control water. DC vaccines (bone marrow-derived DC pulsed with A20 tumor lysate) were injected on days 5 and 9 (s.c., 106 DC per mouse). On day 21, mice were euthanized and the number of liver metastases was determined by two investigators. Spleens and lymph nodes were removed and dissociated, and Treg frequency was assessed as described above. Splenocytes (1 x 105) from control, imatinib-treated, DC-vaccinated or imatinib plus DC-treated mice were cultured for 48 h in 200 µl of complete medium and IFN-{gamma} secretion in the culture supernatants was detected by ELISA.

Statistical analysis

Unless specified otherwise, all experiments were reproduced three times and performed in triplicate. A two-sided Student’s t test with paired samples was used to determine significant differences (p < 0.05) between groups.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Disclosures
 References
 
Sensitivity of CD4+CD25+FoxP3+ Treg to imatinib mesylate in vitro

The phenotypic characterization of Treg in the mouse is primarily based on the expression of the transcription factor FoxP3 involved in their lineage commitment, development, and function (32, 33). The majority of CD4+CD25+ T cells isolated by magnetic cell sorting from the lymphoid tissues of BALB/c mice expressed FoxP3 (Fig. 1A). In addition, purified CD4+CD25+ cells inhibited the proliferation of CD4+CD25– cells induced by APC (Fig. 1B), further demonstrating the immunosuppressive nature of these cells.


Figure 1
View larger version (38K):
[in this window]
[in a new window]

  		FIGURE 1. Sensitivity of Treg to imatinib mesylate. A, CD4+CD25+ but not CD4+CD25– T cells purified from BALB/c mouse spleen and lymph nodes by magnetic cell sorting express FoxP3. Cells were stained with an anti-FoxP3 Ab (FJK-16S; eBioscience) and analyzed by flow cytometry. Representative histograms of nine independent experiments are presented. FoxP3 was expressed consistently by 80–95% of purified CD4+CD25+ T cells. B, Inhibition of the proliferation of CD4+CD25– cells by CD4+CD25+ T lymphocytes. Responder BALB/c CD4+CD25– T cells were stimulated with APC (CD90-depleted C57BL6 splenocytes) in the presence or absence of CD4+CD25+ T cells. The data are shown as means ± SD of triplicate wells of [3H]thymidine incorporation. Results are representative of three independent experiments. *, Significant difference when compared with the corresponding control without CD4+CD25+ cells (p < 0.01). C, Purified CD4+CD25+ Treg or CD4+CD25– T cells were pre-activated with anti-CD3, anti-CD28, and IL-2, and were exposed for 48 h to the indicated concentrations of imatinib mesylate. The BCR-ABL+ imatinib-sensitive 12B1 leukemia was used as positive control. Cell viability was determined by MTT assays. D, Purified CD4+CD25+ Treg were activated with anti-CD3, anti-CD28 Ab, and IL-2, were then exposed for 72 h to the indicated concentration of imatinib mesylate, and cell viability was assessed using MTT. Similar results were obtained with resting Treg cultured for 72 h with imatinib mesylate in presence of anti-CD3, anti-CD28 Ab and IL-2.

 
We first evaluated a possible direct cytotoxic effect of imatinib mesylate against Treg in vitro. Splenic and lymph node CD4+CD25+ and CD4+CD25– T lymphocytes activated and cultured as described in Materials and Methods were exposed to increasing concentrations of imatinib. The mouse leukemia cell line 12B1 expressing the p210 bcr-abl protein and sensitive to imatinib (34, 35) was used as positive control. Only high and continuous concentrations of the drug (>10 µM) affected the viability of CD4+CD25+ Treg over an incubation period of 48 h (Fig. 1C). Of note, patients treated with 400 mg of imatinib daily, or mice receiving 200 mg/kg imatinib daily, achieve peak plasma concentrations of only 1–10 µM (36, 37). CD4+CD25+ and CD4+CD25– cells did not exhibit differential sensitivity to the drug at these concentrations (Fig. 1C). Treg exposure to doses of imatinib achieved clinically for more than 48 h resulted in the reduction of cell viability (Fig. 1D). Concentrations of imatinib of <10 µM and exposure time of 48 h or less were therefore used in further in vitro experiments. Similar results were obtained with Treg isolated from the spleen and draining lymph nodes of mice bearing 12B1 leukemia or A20 lymphoma (data not shown).

Imatinib mesylate minimally affects Treg proliferation in vitro

We next investigated the influence of imatinib on Treg proliferation in vitro. Treg anergic state to TCR-mediated stimulation in vitro can be broken with the combination of anti-CD3/CD28 Abs and IL-2 (38). CD4+CD25+ and CD4+CD25– cells isolated from mouse lymphoid tissues were stimulated under these conditions in the presence of imatinib mesylate at different concentrations for 48 h. Consistent with previous studies (4, 5), imatinib at 10 µM slightly but significantly decreased the proliferation of nonregulatory T lymphocytes. However, non-Treg cell proliferation was not significantly affected by the drug used at lower concentrations (Fig. 2). Treg proliferation was not significantly modified by imatinib treatment of the cells (Fig. 2).


Figure 2
View larger version (24K):
[in this window]
[in a new window]

  		FIGURE 2. Effects of imatinib mesylate on Treg proliferation in vitro. CD4+CD25+ Treg (CD25+Treg) and CD4+CD25– cells (CD25–) were isolated from BALB/c mouse lymphoid tissues and were cultured for a total of 48 h with plate-bound anti-CD3, soluble anti-CD28 and IL-2 with imatinib mesylate at the indicated concentrations. [3H]thymidine was added during the last 12 h. Results are representative of three independent experiments performed in triplicate. *, Significant difference when compared with the control without imatinib (p < 0.05).

 
Imatinib mesylate inhibits Treg immunosuppressive function and FoxP3 expression

To further document the effects of imatinib mesylate on Treg, imatinib-treated or untreated CD4+CD25+ lymphocytes were tested for their immunosuppressive function. Treg isolated from BALB/c mouse lymphoid tissues were activated with anti-CD3, anti-CD28 Abs, and IL-2. The cells were then exposed to nontoxic concentrations of imatinib mesylate (Fig. 1C) for 48 h and then washed. Their ability to inhibit the allo-response of BALB/c CD4+CD25– T lymphocytes to mitomycin C-treated C57BL6 APC was then evaluated. The data depicted in Fig. 3A indicate that imatinib mesylate inhibited the capacity of Treg to suppress CD4+CD25– cell proliferation in a dose-dependent manner.


Figure 3
View larger version (21K):
[in this window]
[in a new window]

  		FIGURE 3. Imatinib mesylate hampers Treg suppressive activity and FoxP3 expression. CD4+CD25+ Treg from lymphoid tissues of BALB/c mice were exposed to increasing but nontoxic concentrations of imatinib mesylate for 48 h, recovered, and washed three times in complete medium to eliminate residual imatinib mesylate. A, The effect of treated or untreated Treg on the proliferation of responder CD4+CD25– T lymphocytes (CD25–) stimulated with mitomycin C-treated allogeneic APC was determined by [3H]thymidine incorporation assays. *, p < 0.02; **, p < 0.005. B, Expression of FoxP3 in CD4+CD25+ Treg treated for 48 h with the indicated concentrations of imatinib. Representative results of three independent experiments. C, TGF-β1 concentration was assessed by ELISA in imatinib mesylate-treated (48 h) CD4+CD25+ Treg (CD25+Treg) or CD4+CD25– T cell (CD25–) cultures. No significant difference was found between groups. Representative results of two independent experiments.

 
The transcription factor FoxP3 is required for the induction of Treg suppressive function, and its expression in nonregulatory cells converts them into immunosuppressive cells (32). Therefore, based on the results presented in Fig. 3A, we reasoned that imatinib may negatively modulate FoxP3 expression in Treg. To test this hypothesis, CD4+CD25+ T cells purified from lymphoid tissues and activated as previously described, were treated with imatinib mesylate. Flow cytometry analysis demonstrated a dose-dependent reduction in the proportion of FoxP3-expressing CD4+CD25+ cells (Fig. 3B).

The influence of imatinib on the production of the immunosuppressive cytokines TGF-β and IL-10 reported to be involved in Treg activity was then examined. Treg or CD4+CD25– cells were isolated and activated as previously mentioned and were exposed to imatinib mesylate for 48 h. The concentration of TGF-β1 in Treg culture supernatants was low and not significantly impaired by imatinib (Fig. 3C). Similarly, imatinib did not significantly affect IL-10 secretion by Treg (data not shown). This result suggests that imatinib mesylate may reduce Treg activity independently of its effect on TGF-β or IL-10.

Imatinib mesylate down-regulates STAT3 and STAT5 phosphorylation in Treg

We have previously mentioned that the induction and persistence of Treg immunosuppressive function is intimately related to FoxP3 expression. The activation of the transcription factor STAT3 following TCR/CD28 costimulation has recently been highlighted as a major molecular event required for FoxP3 expression (39). Indeed, activated STAT3 may be necessary for the maintenance of FoxP3 expression in naturally occurring Treg and may also play a critical role in the conversion of CD4+CD25– cells into CD4+CD25+FoxP3+ Treg (39). In addition, it has been reported that FoxP3 up-regulation in Treg may involve the binding of the STAT3 and STAT5 proteins to a highly conserved STAT-binding site located in the first intron of the FOXP3 gene (40). Based on this information and on the results presented in Fig. 3, we hypothesized that treatment of Treg with this tyrosine kinase inhibitor may result in a negative regulation of these two key transcription factors. Purified CD4+CD25+ or CD4+CD25– pre-exposed to imatinib for 2 h were stimulated with anti-CD3 and anti-CD28 Abs for 6 h. The phosphorylation of STAT3 and STAT5 was then determined by Western blot. Consistent with previous studies, STAT3 was constitutively expressed in both Treg and CD4+CD25– T cells (Fig. 4A). STAT3 Tyr705 phosphorylation induced in Treg by TCR/CD28 signals was impeded by imatinib treatment (Fig. 4A). A down-regulation of STAT3 phosphorylation by the tyrosine kinase inhibitor was also observed in CD4+CD25– cells (Fig. 4A). Consistent with these results, ELISA transcription factor assays demonstrated that imatinib inhibited Treg STAT3 activation (data not shown). STAT5 Tyr694 phosphorylation was also impaired by imatinib in Treg. In CD4+CD25– T lymphocytes the level of STAT5 phosphorylation was low and further reduced by imatinib treatment (Fig. 4A).


Figure 4
View larger version (70K):
[in this window]
[in a new window]

  		FIGURE 4. Imatinib mesylate reduces phosphorylation of key cell signaling molecules in Treg. CD4+CD25– or CD4+CD25+ T cells isolated from BALB/c mouse lymphoid tissues were pre-incubated for 2 h with or without the indicated concentration of imatinib. A, For phospho-STAT3 and Phospho-STAT5 detection, cells were then activated for 6 h with anti-CD3 and anti-CD28 Ab. Equivalent amounts of protein from cell lysates were separated by SDS-PAGE and Western blot analysis was then performed using anti-phospho STAT3, anti-STAT3, anti-phospho STAT5, or anti-STAT5 Abs. B, For the analysis of imatinib interference with early TCR signaling events, cells were activated for 5 min with anti-CD3 and anti-CD28 Abs and blots were probed with anti-phospho ZAP70, anti-ZAP70, anti-phospho LAT or anti-LAT Abs. Untreated, nonactivated cells were used as controls (NA).

 
Imatinib mesylate impairs TCR-induced ZAP70 and LAT phosphorylation in Treg

Imatinib mesylate has been designed as a tyrosine kinase inhibitor, selective to a restricted number of proteins including the ABL tyrosine kinases. However, it has also been reported that, in conventional nonregulatory T lymphocytes, imatinib may impede TCR-dependent T cell activation by inhibiting the src-family tyrosine kinase Lck involved in the recruitment and activation of the protein ZAP70 during the transduction of the TCR-CD3 signals (4). Lck phosphorylates the ITAM motifs on the TCR subunits leading to the recruitment and activation of ZAP70. In turn, activated ZAP70 catalyzes the phosphorylation of the adaptor protein linker of activated T cells (LAT), which then initiates a series of downstream intracellular signal transduction events. Treg thymic differentiation or peripheral conversion depends on signals relayed by the TCR and CD28 (17, 41), and it has been reported that Lck activation is required for STAT3 and FoxP3 induction in Treg (39, 42). To further document the molecular mechanisms underlying Treg inhibition by imatinib, we sought to determine whether it may interfere at this level of the cell signaling cascade in Treg. Purified Treg or CD4+CD25– T cells were preincubated for 2 h with imatinib mesylate, were then stimulated for 5 min with anti-CD3 and anti-CD28 to trigger TCR/CD28 signaling, and the phosphorylation status of ZAP70 and LAT was examined as described (4). As depicted in Fig. 4B, decreased ZAP-70 phosphorylation was observed in Treg cells exposed to imatinib. Consistent with this data, phopho-LAT levels were also reduced by imatinib (Fig. 4B). The phosphorylation of these two signaling molecules was also impaired by the drug in CD4+CD25– T lymphocytes, confirming published data (4).

Overall, these results indicate that as in conventional T cells, imatinib negatively interferes with the proximal TCR/CD28 signaling events, which may account for the down-regulation of Treg key transcriptions factors STAT3, STAT5, and FoxP3 and the observed inhibition of the suppressive function of these cells.

Imatinib mesylate treatment reduces Treg frequency and immunosuppressive function in vivo

We next sought to evaluate whether imatinib may compromise immunosuppressive Treg in vivo. Experiments were designed to first determine the influence of this drug on the relative frequency of Treg in naive animals. BALB/c mice were treated for 7 days with imatinib mesylate (gavage, 300 mg/kg daily). We have documented that this dose is well tolerated in mice with no observed toxicity (34). In other murine models of CML, comparable doses were reported to be well tolerated for as long as 118 days, with peak plasma concentrations of 6.5 µM (37, 43). These levels are below the toxic concentrations for Treg that we have observed in vitro (Fig. 1). Spleens and draining lymph nodes were removed 2 days following the end of imatinib mesylate treatment, and the proportion of CD4+CD25+FoxP3+ cells was assessed by flow cytometry. Our results indicate that the percentage of CD4+CD25+ and FoxP3+CD4+ T cells within the total CD4+ cell population was significantly reduced in mice treated with imatinib. The number of CD25+ cells coexpressing FoxP3 was also negatively affected by imatinib treatment (Fig. 5A).


Figure 5
View larger version (26K):
[in this window]
[in a new window]

  		FIGURE 5. Imatinib mesylate restraints Treg in vivo. A, Imatinib mesylate decreases the frequency of Treg in vivo. Spleens and lymph nodes from naive BALB/c mice treated with imatinib (Imat., gavage, 300 mg/kg, twice daily for 7 days) or with control water (CT), were stained with anti-CD4, anti-CD25, and anti-FoxP3 Abs, and then analyzed by flow cytometry. Characteristic dot plots are depicted. The indicated cell ratios (mean ± SD) were then determined. A significant reduction of CD4+CD25+/CD4+, FoxP3+CD4+/CD4+, and FoxP3+CD4+/CD25+ ratios was detected (p < 0.005, p < 0.002, and p < 0.002, respectively). Representative results of two independent experiments, n = 8 mice per group. B, Imatinib mesylate treatment of naive BALB/c mice reduces Treg immunosuppressive activity. CD4+CD25+ Treg were isolated from lymphoid tissues of BALB/c mice treated with imatinib (Imat., gavage, 300 mg/kg, twice daily for 7 days) or with control vehicle only (CT). Treg ability to suppress the proliferation of CD4+CD25– T cells from naive tumor-free mice was then evaluated as previously described. Representative results of two independent experiments. *, p < 0.01.

 
To further define whether imatinib may modulate the suppressive activity of Treg in vivo, naive tumor-free BALB/c mice were treated with the tyrosine kinase inhibitor (gavage, 300 mg/kg daily), and CD4+CD25+ cells were isolated from the lymphoid tissues by magnetic cell sorting. The cells were tested for their ability to suppress proliferation of nonregulatory CD4+CD25– T lymphocytes purified from naive tumor-free mice. Our results indicate that the immunosuppressive activity of Treg from imatinib-treated mice was compromised when compared with Treg from mice treated with control vehicle (Fig. 5B). Together, these results indicate that a short course of imatinib given to mice orally for 7 days not only reduced the relative number of Treg in vivo, but also inhibited their immunosuppressive activity on a per cell basis.

Imatinib mesylate can be efficiently combined with pulsed DC vaccine to treat established BCR-ABL– A20 lymphoma

The therapeutic depletion of Treg improves responses to cancer immunotherapy (20, 27). Because imatinib impaired Treg activity in vitro and in vivo, we next assessed whether this drug may augment the efficiency of cancer vaccination using a mouse model of imatinib-resistant tumors. A20 leukemia/lymphoma cells (BCR-ABL–) are not sensitive in vitro to concentrations of imatinib that can be achieved in vivo (Fig. 6A). Confirming these results, imatinib treatment of SCID mice bearing A20 with the tyrosine kinase inhibitor (gavage, 300 mg/kg daily for 7 days) did not affect tumor growth compared with untreated animals (Fig. 6B). Very few dying cells were detected within A20 tumor nodules in mice treated with imatinib, further demonstrating that imatinib does not exert direct killing against A20 cells in vivo (Fig. 6C).


Figure 6
View larger version (89K):
[in this window]
[in a new window]

  		FIGURE 6. The A20 lymphoma is insensitive to the direct cytotoxic effects of imatinib mesylate. A, A20 tumor cells (105) were cultured in 96-well plate in complete medium with the indicated concentrations of imatinib for 48 h. Cell viability was then evaluated using MTT assays. The BCR-ABL+ leukemia cell line 12B1 was used as positive control. Representative results of three experiments are shown. B, A20 tumor cells (3 x 106) were injected (s.c.) in the right groin of SCID mice. When tumors became palpable, mice were treated with imatinib (gavage, 300 mg/kg, twice daily for 7 days) and tumor volume was measured every 3 days. C, Detection of dead cells in A20 tumor nodules from mice treated or not with imatinib. Tumors were removed two days after the end of imatinib treatment and tumor sections from untreated (Control) or imatinib-treated (Imatinib) mice were stained using Abs against the cleaved isoform of caspase 3. Dead cells (positive for cleaved caspase 3) were visualized under microscopy. A representative field is shown (x100 magnification). 12B1 tumors from imatinib treated or untreated SCID mice were used as controls.

 
To evaluate the potential synergistic effects of imatinib with tumor immunization, BALB/c mice inoculated (i.v.) with A20 cells were treated with imatinib mesylate and vaccinated twice with DCs pulsed with A20 lysates as described in Fig. 7. The number of liver metastases (Fig. 7A and Supplemental Fig. S1)4 was significantly reduced in mice treated with imatinib plus DC pulsed with tumor lysates compared with control mice or to mice receiving imatinib mesylate or vaccination alone. Splenocytes from control, imatinib-treated, vaccinated, or imatinib plus vaccine-treated mice were cultured for 48 h and IFN-{gamma} concentration was detected by ELISA. Total splenocytes from mice treated with the combination therapy produced significantly higher amounts of IFN-{gamma} compared with the other groups (Fig. 7B). Further analysis indicated that IFN-{gamma} was produced by both CD4+ and CD8+ T lymphocytes (data not shown). Interestingly, analysis of each individual mouse in the group treated with the combination therapy revealed a negative correlation between the levels of IFN-{gamma} and the number of liver metastases (Fig. 7C). Additionally, the frequency of Treg was significantly decreased following treatment of tumor-bearing mice with imatinib plus DC vaccine combination treatment (Fig. 8). These results thus demonstrate that imatinib promotes the antitumor response to vaccination against cancers that are not sensitive to the drug’s direct cytotoxicity.


Figure 7
View larger version (13K):
[in this window]
[in a new window]

  		FIGURE 7. Imatinib mesylate enhances DC based immunization. Female BALB/c mice (eight mice per group) inoculated at day 0 with A20 cells (5 x 105 cells, tail vein injection) were treated with imatinib mesylate (gavage, 300 mg/kg, twice daily for 7 days) or control water. DC vaccination (bone marrow-derived DC pulsed with A20 tumor lysate) was given at days 5 and 9 (s.c., 106 DC per mouse). On day 21 mice were euthanized and the number of liver metastases was determined by two investigators (A). *, p < 0.05. IFN-{gamma} concentration in the supernatants of cultured spleen cells (1 x 105 cells in 200 µl medium/well) from each individual mouse was detected by ELISA after 48 h incubation (B). *, p < 0.05. In the group of mice treated with the combination therapy a negative correlation was found between the levels of IFN-{gamma} produced by splenocytes and the number of liver metastases (C).

 

Figure 8
View larger version (17K):
[in this window]
[in a new window]

  		FIGURE 8. Decrease of Treg following imatinib treatment with or without DC vaccination of A20 tumor-bearing mice. A20 tumor-bearing mice were treated with control vehicle, imatinib, DC, or imatinib plus DC as described in Fig. 7. The number of Treg in spleens and lymph nodes was then determined by flow cytometry. Representative results of two independent experiments. *, p < 0.001.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Disclosures
 References
 
CD4+CD25+FoxP3+ Treg represent major contributors of tumor-induced tolerance. The benefit of integrating Treg neutralization or elimination in cancer immunotherapy strategies has been advocated in several studies (20, 27, 28, 44). We report in this study that the widely used tyrosine kinase inhibitor imatinib mesylate may represent an additional approach to suppress Treg and may therefore be efficiently combined with immunotherapy against imatinib-resistant tumors. Treg immunosuppressive function and FoxP3 expression are impaired by therapeutic concentrations of imatinib but Treg proliferation is not significantly modified by the inhibitor in vitro. In contrast, a recent study reported inhibition of CD4+CD25+ T cell proliferation after treatment for 72 h with imatinib (45). However, we found that continuous exposure of activated Treg to imatinib in vitro for period of time exceeding 48 h results in a significant loss of cell viability, which may explain the reduced BrdU incorporation observed in this report.

We attempted to further identify the molecular mechanisms underlying imatinib-mediated inhibition of Treg activity. The survival, homeostasis and immunosuppressive function of regulatory T cells are dependent on external signals, some of which are relayed by the TCR, CD28, the IL-2 receptor, CTLA-4, GITR, or TGF-β receptors and other yet to be identified molecules (17, 19), converging toward the regulation of specific gene expression such as FoxP3. Particularly, activated STAT3 and STAT5 are required for FoxP3 up-regulation in Treg (39, 40). In line with the observed inhibition of FoxP3 expression, the phosphorylation of both transcription factors STAT3 and STAT5 is attenuated by imatinib mesylate. Previous studies have reported that imatinib hinders TCR-dependent activation of conventional T lymphocytes, highlighting the src-family tyrosine kinase Lck as a possible molecular target of this drug (4). In Treg, CD28-induced Lck activation is critical for STAT3 induction (39). These data prompted us to examine whether imatinib mesylate may interfere with these TCR/CD28 early cell signaling events in Treg. The tyrosine kinase inhibitor alters the phosphorylation status of ZAP-70 and LAT, located immediately downstream Lck in the signal transduction cascade. These observations thus substantiate and provide a molecular basis for the attenuation of Treg suppressive activity by imatinib. However, if the intracellular events leading to conventional T lymphocyte activation are well-characterized, the signaling pathways and their regulation controlling Treg activity are more elusive, and it is thus possible that imatinib suppresses other unidentified key tyrosine kinases involved in the immunosuppressive function of these cells.

Modulation of Treg activity by imatinib mesylate in vivo had not been studied. In line with our in vitro observations, treatment of animals for 7 days with imatinib reduced Treg number and dampened their suppressive function. The potential benefit of combining imatinib with immunotherapy to treat CML patients has been highlighted in different clinical trials (46, 47). We have previously documented that imatinib mesylate can be successfully combined with specific antitumor vaccination to treat established BCR-ABL+ leukemia in mouse (48). However, because imatinib directly induces BCR-ABL+ leukemia cell death, the observed synergistic effects with tumor vaccination could be related to the extensive release of tumor Ags as well as "danger," proinflammatory signals associated with the liberation of the intracellular contents of the cells. The distinction between the killing effects of imatinib and its immunomodulatory function was therefore difficult to ascertain. Thus, although imatinib has been successfully combined with tumor vaccines to treat cancers that are sensitive to the cytotoxic effects of this drug, the integration of imatinib in chemoimmunotherapeutic strategies to treat malignancies that are resistant to direct killing by this molecule had not been previously examined. We therefore sought to further investigate the physiologic relevance of Treg inhibition by imatinib using a tumor model, A20 lymphoma, that is resistant to the cytotoxic activity of the drug. Such an approach allowed for the evaluation of the synergistic effects of imatinib with immunotherapy separately from its direct tumoricidal properties. The dose of imatinib given to animals lead to plasma levels comparable to the concentrations used to treat cells in vitro (37, 43). Our data demonstrate that imatinib significantly enhances the efficacy of DC-based immunization, resulting in a reduction of the number of liver metastases that correlates with higher IFN-{gamma} production by the splenocytes of treated animals. These results thus provide the proof of principle that imatinib can be successfully incorporated in immunotherapy protocols against imatinib resistant tumors. Although humans differ from mice in many different aspects (genetic heterogeneity, personal medical history, previous immunosuppressive therapies, etc.), our data further support previous studies indicating that imatinib may improve responses to tumor-specific vaccination (46, 47, 49, 50).

Our current findings uncover Treg as novel targets for imatinib mesylate and further advocate for the combination of this tyrosine kinase inhibitor with tumor vaccination strategies against malignancies that are typically not affected by imatinib alone. The therapeutic applications of this well-tolerated drug may thus be broadened with its use as an immunomodulator in cancer chemoimmunotherapy protocols.


   Disclosures
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
References
 
The authors have no financial conflict of interest.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported in part by the National Institutes of Health Grant R01 CA104926, the Leukemia and Lymphoma Society Fellow Award 5188-07 (to N.L.), the Tee Up for Tots, and Raise a Racquet for Kids Funds. Back

2 Address correspondence and reprint requests to Dr. Nicolas Larmonier, University of Arizona, Department of Pediatrics, 1501 North Campbell Avenue, PO Box 245073, Tucson, Arizona 85724-5073. E-mail address: nrlarmon{at}email.arizona.edu Back

3 Abbreviations used in this paper: CML, chronic myelogenous leukemia; DC, dendritic cell; Treg, regulatory T cell; ABL, Abelson; LAT, linker of activation of T cell; FoxP3, Forkhead box P3; Lck, leukocyte-specific protein tyrosine kinase. Back

4 The online version of this article contains supplemental material. Back

Received for publication May 28, 2008. Accepted for publication September 12, 2008.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 

  1. Druker, B. J., N. B. Lydon. 2000. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J. Clin. Invest. 105: 3-7. [Medline]
  2. Savage, D. G., K. H. Antman. 2002. Imatinib mesylate: a new oral targeted therapy. N. Engl. J. Med. 346: 683-693. [Free Full Text]
  3. Carroll, M., S. Ohno-Jones, S. Tamura, E. Buchdunger, J. Zimmermann, N. B. Lydon, D. G. Gilliland, B. J. Druker. 1997. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 90: 4947-4952. [Abstract/Free Full Text]
  4. Seggewiss, R., K. Lore, E. Greiner, M. K. Magnusson, D. A. Price, D. C. Douek, C. E. Dunbar, A. Wiestner. 2005. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 105: 2473-2479.
  5. Dietz, A. B., L. Souan, G. J. Knutson, P. A. Bulur, M. R. Litzow, S. Vuk-Pavlovic. 2004. Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood 104: 1094-1099. [Abstract/Free Full Text]
  6. Mumprecht, S., M. Matter, V. Pavelic, A. F. Ochsenbein. 2006. Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections. Blood 108: 3406-3413. [Abstract/Free Full Text]
  7. Chen, J., A. Schmitt, B. Chen, M. Rojewski, M. Ringhoffer, S. von Harsdorf, J. Greiner, P. Guillaume, H. Dohner, D. Bunjes, M. Schmitt. 2007. Imatinib impairs CD8+ T lymphocytes specifically directed against the leukemia-associated antigen RHAMM/CD168 in vitro. Cancer Immunol. Immunother. 56: 849-861. [Medline]
  8. Boissel, N., P. Rousselot, E. Raffoux, J. M. Cayuela, J. Soulier, N. Mooney, D. Charron, H. Dombret, A. Toubert, D. Rea. 2006. Imatinib mesylate minimally affects bcr-abl+ and normal monocyte-derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell-T cell activation. J. Leukocyte Biol. 79: 747-756. [Abstract/Free Full Text]
  9. Gao, H., B. N. Lee, M. Talpaz, N. J. Donato, J. E. Cortes, H. M. Kantarjian, J. M. Reuben. 2005. Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia. Leukemia 19: 1905-1911. [Medline]
  10. Appel, S., A. Rupf, M. M. Weck, O. Schoor, T. H. Brummendorf, T. Weinschenk, F. Grunebach, P. Brossart. 2005. Effects of imatinib on monocyte-derived dendritic cells are mediated by inhibition of nuclear factor-{kappa}B and Akt signaling pathways. Clin. Cancer Res. 11: 1928-1940. [Abstract/Free Full Text]
  11. Appel, S., A. M. Boehmler, F. Grunebach, M. R. Muller, A. Rupf, M. M. Weck, U. Hartmann, V. L. Reichardt, L. Kanz, T. H. Brummendorf, P. Brossart. 2004. Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells. Blood 103: 538-544. [Abstract/Free Full Text]
  12. Taieb, J., K. Maruyama, C. Borg, M. Terme, L. Zitvogel. 2004. Imatinib mesylate impairs Flt3L-mediated dendritic cell expansion and antitumor effects in vivo. Blood 103: 1966-1967. [Free Full Text]
  13. Wehner, R., M. Wendisch, K. Schakel, M. Bornhauser, U. Platzbecker, B. Mohr, A. Temme, M. Bachmann, E. P. Rieber, M. Schmitz. 2006. Imatinib mesylate does not impair the immunogenicity of human myeloid blood dendritic cells. Leukemia 20: 1629-1632. [Medline]
  14. Wang, H., F. Cheng, A. Cuenca, P. Horna, Z. Zheng, K. Bhalla, E. M. Sotomayor. 2005. Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance. Blood 105: 1135-1143. [Abstract/Free Full Text]
  15. Borg, C., M. Terme, J. Taieb, C. Menard, C. Flament, C. Robert, K. Maruyama, H. Wakasugi, E. Angevin, K. Thielemans, et al 2004. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J. Clin. Invest. 114: 379-388. [Medline]
  16. Sakaguchi, S., M. Ono, R. Setoguchi, H. Yagi, S. Hori, Z. Fehervari, J. Shimizu, T. Takahashi, T. Nomura. 2006. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol. Rev. 212: 8-27. [Medline]
  17. Shevach, E. M.. 2002. CD4+ CD25+ suppressor T cells: more questions than answers. Nat. Rev. Immunol. 2: 389-400. [Medline]
  18. Antony, P. A., C. A. Piccirillo, A. Akpinarli, S. E. Finkelstein, P. J. Speiss, D. R. Surman, D. C. Palmer, C. C. Chan, C. A. Klebanoff, W. W. Overwijk, et al 2005. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 174: 2591-2601. [Abstract/Free Full Text]
  19. Sakaguchi, S.. 2000. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 101: 455-458. [Medline]
  20. Ghiringhelli, F., N. Larmonier, E. Schmitt, A. Parcellier, D. Cathelin, C. Garrido, B. Chauffert, E. Solary, B. Bonnotte, F. Martin. 2004. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol. 34: 336-344. [Medline]
  21. Liyanage, U. K., T. T. Moore, H. G. Joo, Y. Tanaka, V. Herrmann, G. Doherty, J. A. Drebin, S. M. Strasberg, T. J. Eberlein, P. S. Goedegebuure, D. C. Linehan. 2002. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 169: 2756-2761. [Abstract/Free Full Text]
  22. Viguier, M., F. Lemaitre, O. Verola, M. S. Cho, G. Gorochov, L. Dubertret, H. Bachelez, P. Kourilsky, L. Ferradini. 2004. Foxp3 expressing CD4+CD25high regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J. Immunol. 173: 1444-1453. [Abstract/Free Full Text]
  23. Larmonier, N., M. Marron, Y. Zeng, J. Cantrell, A. Romanoski, M. Sepassi, S. Thompson, X. Chen, S. Andreansky, E. Katsanis. 2007. Tumor-derived CD4+CD25+ regulatory T cell suppression of dendritic cell function involves TGF-β and IL-10. Cancer Immunol. Immunother. 56: 48-59. [Medline]
  24. Valzasina, B., S. Piconese, C. Guiducci, M. P. Colombo. 2006. Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25– lymphocytes is thymus and proliferation independent. Cancer Res. 66: 4488-4495. [Abstract/Free Full Text]
  25. Ghiringhelli, F., P. E. Puig, S. Roux, A. Parcellier, E. Schmitt, E. Solary, G. Kroemer, F. Martin, B. Chauffert, L. Zitvogel. 2005. Tumor cells convert immature myeloid dendritic cells into TGF-β-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J. Exp. Med. 202: 919-929. [Abstract/Free Full Text]
  26. Larmonier, N., J. Cantrell, C. Lacasse, G. Li, N. Janikashvili, E. Situ, M. Sepassi, S. Andreansky, E. Katsanis. 2008. Chaperone-rich tumor cell lysate-mediated activation of antigen-presenting cells resists regulatory T cell suppression. J. Leukocyte Biol. 83: 1049-1059. [Abstract/Free Full Text]
  27. Prasad, S. J., K. J. Farrand, S. A. Matthews, J. H. Chang, R. S. McHugh, F. Ronchese. 2005. Dendritic cells loaded with stressed tumor cells elicit long-lasting protective tumor immunity in mice depleted of CD4+CD25+ regulatory T cells. J. Immunol. 174: 90-98. [Abstract/Free Full Text]
  28. Dannull, J., Z. Su, D. Rizzieri, B. K. Yang, D. Coleman, D. Yancey, A. Zhang, P. Dahm, N. Chao, E. Gilboa, J. Vieweg. 2005. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 115: 3623-3633. [Medline]
  29. Attia, P., D. J. Powell, Jr, A. V. Maker, R. J. Kreitman, I. Pastan, S. A. Rosenberg. 2006. Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2. J. Immunother. 29: 208-214. [Medline]
  30. Valzasina, B., C. Guiducci, H. Dislich, N. Killeen, A. D. Weinberg, M. P. Colombo. 2005. Triggering of OX40 (CD134) on CD4+CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood 105: 2845-2851.
  31. Comes, A., O. Rosso, A. M. Orengo, E. Di Carlo, C. Sorrentino, R. Meazza, T. Piazza, B. Valzasina, P. Nanni, M. P. Colombo, S. Ferrini. 2006. CD25+ regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine. J. Immunol. 176: 1750-1758. [Abstract/Free Full Text]
  32. Fontenot, J. D., A. Y. Rudensky. 2005. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat. Immunol. 6: 331-337. [Medline]
  33. Gavin, M. A., J. P. Rasmussen, J. D. Fontenot, V. Vasta, V. C. Manganiello, J. A. Beavo, A. Y. Rudensky. 2007. Foxp3-dependent programme of regulatory T-cell differentiation. Nature 445: 771-775. [Medline]
  34. Zeng, Y., M. W. Graner, H. Feng, G. Li, E. Katsanis. 2004. Imatinib mesylate effectively combines with chaperone-rich cell lysate-loaded dendritic cells to treat bcr-abl+ murine leukemia. Int. J. Cancer 110: 251-259. [Medline]
  35. Zeng, Y., X. Chen, N. Larmonier, C. Larmonier, G. Li, M. Sepassi, M. Marron, S. Andreansky, E. Katsanis. 2006. Natural killer cells play a key role in the antitumor immunity generated by chaperone-rich cell lysate vaccination. Int. J. Cancer 119: 2624-2631. [Medline]
  36. Druker, B. J., M. Talpaz, D. J. Resta, B. Peng, E. Buchdunger, J. M. Ford, N. B. Lydon, H. Kantarjian, R. Capdeville, S. Ohno-Jones, C. L. Sawyers. 2001. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344: 1031-1037. [Abstract/Free Full Text]
  37. Wolff, N. C., D. E. Randle, M. J. Egorin, J. D. Minna, R. L. Ilaria, Jr. 2004. Imatinib mesylate efficiently achieves therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer. Clin. Cancer Res. 10: 3528-3534. [Abstract/Free Full Text]
  38. Ring, S., M. Thome, L. Pretsch, A. H. Enk, K. Mahnke. 2007. Expanded murine regulatory T cells: analysis of phenotype and function in contact hypersensitivity reactions. J. Immunol. Methods 326: 10-21. [Medline]
  39. Pallandre, J. R., E. Brillard, G. Crehange, A. Radlovic, J. P. Remy-Martin, P. Saas, P. S. Rohrlich, X. Pivot, X. Ling, P. Tiberghien, C. Borg. 2007. Role of STAT3 in CD4+CD25+FOXP3+ regulatory lymphocyte generation: implications in graft-versus-host disease and antitumor immunity. J. Immunol. 179: 7593-7604. [Abstract/Free Full Text]
  40. Zorn, E., E. A. Nelson, M. Mohseni, F. Porcheray, H. Kim, D. Litsa, R. Bellucci, E. Raderschall, C. Canning, R. J. Soiffer, et al 2006. IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT dependent mechanism and induces the expansion of these cells in vivo. Blood 108: 1571-1579. [Abstract/Free Full Text]
  41. Thornton, A. M., C. A. Piccirillo, E. M. Shevach. 2004. Activation requirements for the induction of CD4+CD25+ T cell suppressor function. Eur. J. Immunol. 34: 366-376. [Medline]
  42. Tai, X., M. Cowan, L. Feigenbaum, A. Singer. 2005. CD28 costimulation of developing thymocytes induces Foxp3 expression and regulatory T cell differentiation independently of interleukin 2. Nat. Immunol. 6: 152-162. [Medline]
  43. Wolff, N. C., J. A. Richardson, M. Egorin, R. L. Ilaria, Jr. 2003. The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia. Blood 101: 5010-5013. [Abstract/Free Full Text]
  44. Knutson, K. L., Y. Dang, H. Lu, J. Lukas, B. Almand, E. Gad, E. Azeke, M. L. Disis. 2006. IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J. Immunol. 177: 84-91. [Abstract/Free Full Text]
  45. Chen, J., A. Schmitt, K. Giannopoulos, B. Chen, M. Rojewski, H. Dohner, D. Bunjes, M. Schmitt. 2007. Imatinib impairs the proliferation and function of CD4+CD25+ regulatory T cells in a dose-dependent manner. Int. J. Oncol. 31: 1133-1139. [Medline]
  46. Bocchia, M., S. Gentili, E. Abruzzese, A. Fanelli, F. Iuliano, A. Tabilio, M. Amabile, F. Forconi, A. Gozzetti, D. Raspadori, et al 2005. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 365: 657-662. [Medline]
  47. Li, Z., Y. Qiao, B. Liu, E. J. Laska, P. Chakravarthi, J. M. Kulko, R. D. Bona, M. Fang, U. Hegde, V. Moyo, et al 2005. Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia. Clin. Cancer Res. 11: 4460-4468. [Abstract/Free Full Text]
  48. Zeng, Y., H. Feng, M. W. Graner, E. Katsanis. 2003. Tumor-derived, chaperone-rich cell lysate activates dendritic cells and elicits potent antitumor immunity. Blood 101: 4485-4491. [Abstract/Free Full Text]
  49. Bocchia, M., E. Abruzzese, F. Forconi, M. Ippoliti, M. M. Trawinska, M. T. Pirrotta, D. Raspadori, M. Tozzi, A. Gozzetti, F. Lauria. 2006. Imatinib does not impair specific antitumor T-cell immunity in patients with chronic myeloid leukemia. Leukemia 20: 142-143. [Medline]
  50. Chen, C. I., H. T. Maecker, P. P. Lee. 2008. Development and dynamics of robust T-cell responses to CML under imatinib treatment. Blood 111: 5342-5349. [Abstract/Free Full Text]




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Larmonier, N.
Right arrow Articles by Katsanis, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Larmonier, N.
Right arrow Articles by Katsanis, E.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS